4.6 Article

Intermediate and Long-term Outcomes of Survivors of Acute Kidney Injury Episodes: A Large Population-Based Cohort Study

Journal

AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 69, Issue 1, Pages 18-28

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2016.05.018

Keywords

Acute kidney injury (AKI); chronic kidney disease (CKD); baseline kidney function; survival mortality; epidemiology; outcomes; prognosis; AKI recovery; acute on chronic kidney disease

Funding

  1. NHS Research Scotland, through NHS Grampian investment in the Grampian Data Safe Haven
  2. Wellcome Trust [102729/Z/13/Z]
  3. Farr Institute of Health Informatics Research
  4. Arthritis Research UK
  5. British Heart Foundation
  6. Cancer Research UK
  7. Economic and Social Research Council
  8. Engineering and Physical Sciences Research Council
  9. Medical Research Council
  10. National Institute of Health Research
  11. National Institute for Social Care and Health Research (Welsh Assembly Government)
  12. Chief Scientist Office (Scottish Government Health Directorates)
  13. Wellcome Trust (Medical Research Council) [Scotland MR/K007017/1]
  14. Medical Research Council [MR/M501633/1, MC_PC_13040, MR/M501633/2, MR/K007017/1] Funding Source: researchfish
  15. MRC [MR/K007017/1, MR/M501633/2] Funding Source: UKRI

Ask authors/readers for more resources

Background: The long-term prognosis after acute kidney injury (AKI) is variable. It is unclear how the prognosis of AKI and its relationship to prognostic factors (baseline kidney function, AKI severity, prior AKI episodes, and recovery of kidney function) change as follow-up progresses. Study Design: Observational cohort study. Setting & Participants: The Grampian Laboratory Outcomes Morbidity and Mortality Study II (GLOMMS-II) is a large regional population cohort with complete serial biochemistry and outcome data capture through data linkage. From GLOMMS-II, we followed up 17,630 patients hospitalized in 2003 through to 2013. Predictors: AKI identified using KDIGO (Kidney Disease: Improving Global Outcomes) serum creatinine criteria, characterized by baseline kidney function (estimated glomerular filtration rate [eGFR] >= 60, 45-59, 30-44, and, 30 mL/min/1.73 m(2)), AKI severity (KDIGOstage), 90-dayrecovery of kidney function, andpriorAKI episodes. Outcomes: Intermediate-(30-364 days) and long-term (1-10 years) mortality and long-term renal replacement therapy. Measurements: Poisson regression in time discrete intervals. Multivariable Cox regression for those at risk in the intermediate and long term, adjusted for age, sex, baseline comorbid conditions, and acute admission circumstances. Results: Of 17,630 patients followed up for a median of 9.0 years, 9,251 died. Estimated incidences of hospital AKI were 8.4% and 17.6% for baseline eGFRs >= 60 and < 60 mL/min/1.73 m(2), respectively. Intermediate-term (30-364 days) adjusted mortality HRs for AKI versus no AKI were 2.48 (95% CI, 2.15-2.88), 2.50 (95% CI, 2.04-3.06), 1.90 (95% CI, 1.51-2.39), and 1.63 (95% CI, 1.20-2.22) for eGFRs >= 60, 45 to 59, 30 to 44, and < 30 mL/min/1.73 m(2), respectively. Among 1-year survivors, long-term HRs were attenuated: 1.44 (95% CI, 1.31-1.58), 1.25 (95% CI, 1.09-1.43), 1.21 (95% CI, 1.03-1.42), and 1.08 (95% CI, 0.85-1.36), respectively. The excess long-term hazards in AKI were lower for lower baseline eGFRs (P for interaction = 0.01). Limitations: Nonprotocolized observational data. No adjustment for albuminuria. Conclusions: The prognostic importance of a discrete AKI episode lessens over time. Baseline kidney function is of greater long-term importance. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available